Bacteria-comprising compositions and methods of using the same for treating and/or preventing gastrointestinal, metabolic and/or other diseases
AssigneeWageningen Universiteit
InventorsWillem Meindert De Vos, Thi Phuong Nam Bui
Life of this patent
Estimating the term…
Abstract
The disclosure is concerned with a novel human intestinal isolate capable of converting L-lysine into butyrate and/or of converting fructose-lysine into butyrate. The novel isolate can be used as a probiotic or supplement to promote production of butyrate in the GI tract, thereby preventing and/or treating conditions or diseases that benefit from the production of butyrate. Additionally, the isolate may prevent and/or treat conditions or diseases caused by an excess of pathogenic bacteria in the GI tract, mediated by L-lysine, or mediated by fructose-lysine or other advanced glycation end products.
Claims19
A method of providing treatment of metabolic syndrome in a subject, the method comprising:
- administering to the subject a bacterium comprising:
- a lysine pathway gene set that enables said bacterium to convert L-lysine into butyric acid, butyrate, or a combination or derivative thereof, and
- a glycated lysine uptake and degradation operon that enables said bacterium to convert glycated lysine into butyric acid, butyrate, or a combination or derivative thereof,
- wherein the lysine pathway gene set encodes at least one of Lysine 2,3-aminomutase, L-beta-lysine 5,6-aminomutase alpha subunit, L-beta-lysine 5,6-aminomutase beta subunit, 3,5-diaminobexanoate dehydrogenase, 3-keto-5-aminohexanoate cleavage enzyme, 3-aminobutyryl-CoA ammonia-lyase, butyrateacetoacetate CoA-transferase subunit A, butyrate-acetoacetate CoA-transferase subunit B, and acetyl-CoA:acetoacetyl-CoA transferase;
- and
- wherein the glycated lysine uptake and degradation operon is a fructose-lysine uptake and degradation operon encoding at least one of fructose-lysine kinase, fructosamine deglycase, ABC transporter periplasmic spermidine putrescine-binding protein PotD, spermidine putrescine ABC transporter permease component PotC, spermidine putrescine ABC transporter permease component PotB, and putrescine transport ATP-binding protein PotA.
A method of treating a subject for metabolic syndrome, wherein the subject has a large intestine, the method comprising:
- administering to the subject a bacterium, wherein the bacterium is Intestinimonas AF211 deposited on Jan. 5, 2015 at the Centraalbureau voor Schimmelcultures located in Utrecht, the Netherlands, and assigned deposit number CBS 139326 or a strain derived therefrom.
Dependencies are inferred from the claim text.